521 GEN-009, a personalized neoantigen vaccine candidate, elicits diverse and durable immune responses associated with clinical efficacy outcomes

• Thomas Davis,
• Jessica Flechtner,
• Mara Shainheit,
• Gabriella Santone,
• Syukri Shukor,
• Ece Bicak,
• Li Xue,
• Emily Tjon,
• Masoud Golshadi

Affiliations

Thomas Davis

Aff3 grid.417695.8Celldex Therapeutics, Inc. Charlottesville VA USA

Jessica Flechtner

Aff1 grid.475330.60000000405579162Genocea Biosciences, Inc Cambridge MA USA

Mara Shainheit

7Genocea Biosciences, Centreville, MD, USA

Gabriella Santone

Genocea Biosciences, Cambridge, MA, USA

Syukri Shukor

Genocea Biosciences, Cambridge, MA, USA

Ece Bicak

Genocea Biosciences, Cambridge, MA, USA

Li Xue

Genocea Biosciences, Cambridge, MA, USA

Emily Tjon

8Genocea, Madison, CT, USA

Masoud Golshadi

Genocea Biosciences, Cambridge, MA, USA